Peptides DB
Research-centric peptide and protocol reference hub

Dulaglutide record · updated 7h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 22 studiesJump to the evidenceCompare
What is Dulaglutide used for?

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used primarily for the treatment of type 2 diabetes. It mimics the action of the endogenous GLP-1 hormone, which is involved in glucose metabolism. The mechanism of action includes stimulating insulin secretion in response to elevated blood glucose levels, inhibiting glucagon release, and slowing gastric emptying, which collectively contribute to improved glycemic control and potential weight loss.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Dulaglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 110 registered trials. It describes the research record, not a recommendation.

Identity
NameDulaglutide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026
Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~5 days
Time to peak24–48 hours
DurationOnce weekly
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Nov 5, 2026. How this works →
Research stats
Total studies22
Human / animal / cellular9 / 1 / 1
Highest trial phasePhase 4
Years covered2023–2026
Latest study1d ago
Publication history
20232026
Research funding
17 NIH projects · $7.6M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports1,589
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

22 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
Finding243,114 GLP-1 primary-suspect case-product records within 8,995,547 background reports.
review2026Full text read0.80
Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.
FindingsHR for mortality on dialysis 0.82 (95% CI 0.70-0.97; 1-year cumulative incidence 11% vs. 13%)
Human2026Full text read0.80
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
Finding8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.
Human2026Full text read0.80
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
FindingGLP-1RA initiation inversely associated with antidepressants (aSR: 0.85; 95% CI: 0.76-0.94)
Human2024Full text read0.80
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
FindingETD for HbA1c reduction: -0.74%; CI95: -0.90, -0.59
Human2026Full text read0.90
Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.
Finding0.16 QALYs gained with icodec versus glargine U100 and degludec.
—2026Full text read0.80
Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.
FindingHR 0.69 for 30% eGFR decline, 95% CI 0.59-0.80, p<0.001
Human2026Full text read0.80
Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Finding−0.25% HbA1c mean difference vs dulaglutide, 95% CI −0.38 to −0.12, p=0.0002
review2026Full text read0.80
Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice.
FindingNot reported in abstract.
Animal2026Full text read0.70
Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations.
Finding$6600 vs $107,992.82, yielding an ICER of -$2.25 million.
review2023Full text read0.80
Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
FindingMD = 2.73 improvement in ED score, 95% CI: 1.64-3.83
review2026Full text read0.80
Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.
FindingAdjusted mean difference for time in very low range was 0.22% (97.5% CI -0.83 to 1.27, p=0.63).
Human2023Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Dulaglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Dulaglutide is discussed should be drawn from it.